Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Denali Therapeutics Inc (NASDAQ: DNLI) was $18.56 for the day, up 0.54% from the previous closing price of $18.46. In other words, the price has increased by $0.54 from its previous closing price. On the day, 1.45 million shares were traded. DNLI stock price reached its highest trading level at $19.17 during the session, while it also had its lowest trading level at $18.28.
Ratios:
Our analysis of DNLI’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 11.79 and its Current Ratio is at 11.79. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on December 13, 2023, initiated with a Buy rating and assigned the stock a target price of $32.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 15 ’24 when SATO VICKI L sold 1,674 shares for $20.39 per share. The transaction valued at 34,133 led to the insider holds 116,369 shares of the business.
SATO VICKI L sold 1,666 shares of DNLI for $30,471 on Apr 15 ’24. The Director now owns 118,043 shares after completing the transaction at $18.29 per share. On Apr 01 ’24, another insider, Krognes Steve E., who serves as the Director of the company, sold 92,500 shares for $20.50 each. As a result, the insider received 1,896,250 and left with 47,341 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNLI now has a Market Capitalization of 2646822912 and an Enterprise Value of 1760500736. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.96 while its Price-to-Book (P/B) ratio in mrq is 1.82. Its current Enterprise Value per Revenue stands at 5.96 whereas that against EBITDA is -8.497.
Stock Price History:
Over the past 52 weeks, DNLI has reached a high of $33.31, while it has fallen to a 52-week low of $14.56. The 50-Day Moving Average of the stock is 0.50%, while the 200-Day Moving Average is calculated to be -5.59%.
Shares Statistics:
DNLI traded an average of 1.08M shares per day over the past three months and 903220 shares per day over the past ten days. A total of 138.39M shares are outstanding, with a floating share count of 117.26M. Insiders hold about 17.78% of the company’s shares, while institutions hold 82.11% stake in the company. Shares short for DNLI as of 1715731200 were 9493348 with a Short Ratio of 8.82, compared to 1713139200 on 9575705. Therefore, it implies a Short% of Shares Outstanding of 9493348 and a Short% of Float of 7.8.
